Exact Mass: 1303.6659498000001

Exact Mass Matches: 1303.6659498000001

Found 4 metabolites which its exact mass value is equals to given mass value 1303.6659498000001, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Icatibant

(2S)-2-({[(3as,7as)-1-{2-[(2S)-2-{[(2S)-2-{[2-({[(4R)-1-[1-(2-{[(2R)-2-amino-5-carbamimidamido-1-hydroxypentylidene]amino}-5-carbamimidamidopentanoyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-(thiophen-2-yl)propylidene]amino}-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carbonyl}-octahydro-1H-indol-2-yl](hydroxy)methylidene}amino)-5-carbamimidamidopentanoate

C59H89N19O13S (1303.6607624000003)

Icatibant (Firazyr) is a peptidomimetic drug consisting of ten amino acids, which is an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States. B - Blood and blood forming organs > B06 - Other hematological agents > B06A - Other hematological agents > B06AC - Drugs used in hereditary angioedema D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D051056 - Complement Inactivating Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D065168 - Bradykinin Receptor Antagonists > D065094 - Bradykinin B2 Receptor Antagonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics COVID info from Guide to PHARMACOLOGY D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Icatibant (HOE-140) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively[1][2][3].

A-1437B

C59H93N13O20 (1303.6659498000001)

Icatibant

(2S)-2-{[(3aS,7aS)-1-({2-[(2S)-2-[(2S)-2-(2-{[(4R)-1-[(1-{2-[(2R)-2-amino-5-[(diaminomethylidene)amino]pentanamido]-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidin-2-yl)carbonyl]-4-hydroxypyrrolidin-2-yl]formamido}acetamido)-3-(thiophen-2-yl)propanamido]-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}carbonyl)-octahydro-1H-indol-2-yl]formamido}-5-[(diaminomethylidene)amino]pentanoic acid

C59H89N19O13S (1303.6607624000003)

Icatibant (HOE-140) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively[1][2][3].

3-{[16-(1-aminoethyl)-31-(1-carboxyethyl)-22,28-bis(carboxymethyl)-6,15,18,21,24,27,30,33-octahydroxy-13-isopropyl-4-methyl-2,12-dioxo-1,5,11,14,17,20,23,26,29,32-decaazatricyclo[32.4.0.0⁷,¹¹]octatriaconta-5,14,17,20,23,26,29,32-octaen-3-yl]-c-hydroxycarbonimidoyl}-3-[(1-hydroxy-12-methyltridec-3-en-1-ylidene)amino]propanoic acid

3-{[16-(1-aminoethyl)-31-(1-carboxyethyl)-22,28-bis(carboxymethyl)-6,15,18,21,24,27,30,33-octahydroxy-13-isopropyl-4-methyl-2,12-dioxo-1,5,11,14,17,20,23,26,29,32-decaazatricyclo[32.4.0.0⁷,¹¹]octatriaconta-5,14,17,20,23,26,29,32-octaen-3-yl]-c-hydroxycarbonimidoyl}-3-[(1-hydroxy-12-methyltridec-3-en-1-ylidene)amino]propanoic acid

C59H93N13O20 (1303.6659498000001)